These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6198895)

  • 1. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    Winkle RA; Keefe DL; Rodriguez I; Kates RE
    Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
    Mead RH; Keefe DL; Kates RE; Winkle RA
    Am J Cardiol; 1985 Jan; 55(1):72-8. PubMed ID: 2578245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.
    Somani P
    Am J Cardiol; 1981 Jul; 48(1):157-63. PubMed ID: 7246437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorcainide disposition kinetics in arrhythmia patients.
    Kates RE; Keefe DL; Winkle RA
    Clin Pharmacol Ther; 1983 Jan; 33(1):28-34. PubMed ID: 6848296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of lorcainide during chronic treatment.
    Meinertz T; Kasper W; Kersting F; Bechtold H; Just H; Jähnchen E
    Arzneimittelforschung; 1980; 30(9):1593-5. PubMed ID: 7193031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of lorcainide.
    Keefe DL
    Am J Cardiol; 1984 Aug; 54(4):18B-21B. PubMed ID: 6465043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    Vlay SC; Mallis GI
    Am Heart J; 1986 Mar; 111(3):452-5. PubMed ID: 3953352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias.
    Keefe DL; Peters F; Winkle RA
    Am Heart J; 1982 Apr; 103(4 Pt 1):511-8. PubMed ID: 7039282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
    Keefe DL; Kates RE; Winkle RA
    J Cardiovasc Pharmacol; 1984; 6(5):808-15. PubMed ID: 6209484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    Echt DS; Mitchell LB; Kates RE; Winkle RA
    Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option.
    Anderson JL; Anastasiou-Nana M; Lutz JR; Writer SL
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):333-41. PubMed ID: 3881497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias.
    Falk RH; O'Brien JL
    Chest; 1984 Oct; 86(4):537-40. PubMed ID: 6383741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistant ventricular arrhythmias treated with lorcainide, a new antiarrhythmic drug.
    Somani P; di Giorgi S
    Chest; 1980 Oct; 78(4):658-60. PubMed ID: 7418495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of antiarrhythmic drugs on stable ventricular premature beats. Controlled comparison of lorcainide and lidocaine.
    Schmidt G; Klein G; Wirtzfeld A
    Eur J Clin Pharmacol; 1985; 27(6):633-6. PubMed ID: 2580712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
    Carmeliet E
    Eur J Pharmacol; 1987 Jan; 133(1):29-36. PubMed ID: 3556390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic effect of lorcainide in patients taking digoxin.
    Giardina EG; Raby K; Saroff AL; Louie-Chu M
    J Clin Pharmacol; 1987; 27(5):378-83. PubMed ID: 3693581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial and long-term outpatient experience with lorcainide for suppression of malignant and potentially malignant ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Hampton EM; Nanas JN; Lutz JR
    Am Heart J; 1985 Dec; 110(6):1168-75. PubMed ID: 4072873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
    Somani P; Temesy-Armos PN; Leighton RF; Goodenday LS; Fraker TD
    Am Heart J; 1984 Dec; 108(6):1443-8. PubMed ID: 6507240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.